Bayer AG (BAYN) Given Consensus Rating of “Buy” by Brokerages
Shares of Bayer AG (FRA:BAYN) have been assigned a consensus recommendation of “Buy” from the twenty-two ratings firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and fourteen have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is €121.80 ($145.00).
A number of research analysts have issued reports on BAYN shares. set a €105.00 ($125.00) target price on Bayer and gave the company a “neutral” rating in a research note on Wednesday, August 23rd. Jefferies Group set a €137.00 ($163.10) price target on Bayer and gave the company a “buy” rating in a report on Wednesday, August 23rd. Warburg Research set a €121.00 ($144.05) price target on Bayer and gave the company a “buy” rating in a report on Wednesday, August 23rd. Independent Research set a €120.00 ($142.86) price target on Bayer and gave the company a “neutral” rating in a report on Wednesday, August 23rd. Finally, UBS set a €125.00 ($148.81) price target on Bayer and gave the company a “buy” rating in a report on Wednesday, August 23rd.
Bayer (FRA BAYN) traded up €0.10 ($0.12) during trading hours on Friday, reaching €106.50 ($126.79). The company’s stock had a trading volume of 6,184,479 shares. Bayer has a 1 year low of €95.48 ($113.67) and a 1 year high of €123.82 ($147.40).
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.